As such, therapeutic antibodies that block PD-L1/PD1 interactions between cancer cells and T cells have recently received great attention because of their capacity to reverse T cell exhaustion in response to persistent antigen stimulation and to improve the immune control of cancer in a variety of tumor types, including melanoma, lung, and renal cell carcinomas (154). This evidence concerns the gene CD274 and neoplasm.